“Wouldn't you agree, that Leronlimab would be wa
Post# of 148253
You completely missed the point as the post was about NP misleading investors.
NEWS2 was reduced in the M2M trial and I suspect a larger trial would show the same. Therefore, leronlimab could be valuable in reducing progression to S/C if given early in the disease to those who are most at risk.